Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/C3_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/C3_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/C3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/C3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/C3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/C3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/C3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/C3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005134616 | Prostate | BPH | negative regulation of hydrolase activity | 94/3107 | 379/18723 | 2.46e-05 | 2.94e-04 | 94 |
GO:007124110 | Prostate | BPH | cellular response to inorganic substance | 62/3107 | 226/18723 | 2.57e-05 | 3.05e-04 | 62 |
GO:00000792 | Prostate | BPH | regulation of cyclin-dependent protein serine/threonine kinase activity | 32/3107 | 94/18723 | 2.79e-05 | 3.27e-04 | 32 |
GO:00002099 | Prostate | BPH | protein polyubiquitination | 64/3107 | 236/18723 | 2.83e-05 | 3.31e-04 | 64 |
GO:00181967 | Prostate | BPH | peptidyl-asparagine modification | 13/3107 | 24/18723 | 2.85e-05 | 3.32e-04 | 13 |
GO:003312010 | Prostate | BPH | positive regulation of RNA splicing | 17/3107 | 37/18723 | 2.89e-05 | 3.34e-04 | 17 |
GO:004639010 | Prostate | BPH | ribose phosphate biosynthetic process | 54/3107 | 190/18723 | 2.90e-05 | 3.34e-04 | 54 |
GO:004315415 | Prostate | BPH | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 28/3107 | 78/18723 | 2.91e-05 | 3.34e-04 | 28 |
GO:00435429 | Prostate | BPH | endothelial cell migration | 73/3107 | 279/18723 | 3.03e-05 | 3.46e-04 | 73 |
GO:00400135 | Prostate | BPH | negative regulation of locomotion | 96/3107 | 391/18723 | 3.11e-05 | 3.54e-04 | 96 |
GO:000863716 | Prostate | BPH | apoptotic mitochondrial changes | 35/3107 | 107/18723 | 3.17e-05 | 3.60e-04 | 35 |
GO:00105086 | Prostate | BPH | positive regulation of autophagy | 39/3107 | 124/18723 | 3.17e-05 | 3.60e-04 | 39 |
GO:00066068 | Prostate | BPH | protein import into nucleus | 46/3107 | 155/18723 | 3.42e-05 | 3.82e-04 | 46 |
GO:007005917 | Prostate | BPH | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 24/3107 | 63/18723 | 3.48e-05 | 3.87e-04 | 24 |
GO:00610148 | Prostate | BPH | positive regulation of mRNA catabolic process | 30/3107 | 87/18723 | 3.72e-05 | 4.04e-04 | 30 |
GO:00068909 | Prostate | BPH | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 21/3107 | 52/18723 | 3.85e-05 | 4.18e-04 | 21 |
GO:00328729 | Prostate | BPH | regulation of stress-activated MAPK cascade | 54/3107 | 192/18723 | 3.97e-05 | 4.28e-04 | 54 |
GO:19900898 | Prostate | BPH | response to nerve growth factor | 22/3107 | 56/18723 | 4.21e-05 | 4.48e-04 | 22 |
GO:00435886 | Prostate | BPH | skin development | 69/3107 | 263/18723 | 4.49e-05 | 4.73e-04 | 69 |
GO:00075656 | Prostate | BPH | female pregnancy | 54/3107 | 193/18723 | 4.64e-05 | 4.87e-04 | 54 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C3 | SNV | Missense_Mutation | novel | c.2800N>C | p.Glu934Gln | p.E934Q | P01024 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
C3 | SNV | Missense_Mutation | | c.1052C>T | p.Ser351Phe | p.S351F | P01024 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
C3 | SNV | Missense_Mutation | rs199911426 | c.4594N>T | p.Arg1532Trp | p.R1532W | P01024 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | | SD |
C3 | SNV | Missense_Mutation | | c.4276N>A | p.Asp1426Asn | p.D1426N | P01024 | protein_coding | deleterious(0.01) | probably_damaging(0.929) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C3 | SNV | Missense_Mutation | | c.3803N>G | p.Ser1268Cys | p.S1268C | P01024 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
C3 | SNV | Missense_Mutation | | c.1376N>T | p.Ser459Leu | p.S459L | P01024 | protein_coding | tolerated(0.09) | possibly_damaging(0.599) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
C3 | SNV | Missense_Mutation | novel | c.4408N>A | p.Glu1470Lys | p.E1470K | P01024 | protein_coding | deleterious(0) | benign(0.188) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C3 | SNV | Missense_Mutation | novel | c.3118G>C | p.Glu1040Gln | p.E1040Q | P01024 | protein_coding | tolerated(0.11) | benign(0.063) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
C3 | SNV | Missense_Mutation | novel | c.2782N>G | p.Ser928Ala | p.S928A | P01024 | protein_coding | tolerated(0.22) | benign(0.007) | TCGA-BH-A0DG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
C3 | SNV | Missense_Mutation | | c.1452N>T | p.Glu484Asp | p.E484D | P01024 | protein_coding | tolerated(0.52) | benign(0.003) | TCGA-D8-A1XG-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | Imprime PGG immunotherapeutic | | |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | POT-4 | | 19025129 |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | COMPSTATIN | COMPSTATIN | 25494040 |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | POT-4 | | |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | APL-2 | PEGCETACOPLAN | |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | clozapine | CLOZAPINE | 26503818 |